ASLAN Pharma Analyst Ratings
ASLAN Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 08/14/2023 | 1263.64% | Roth MKM | → $15 | Reiterates | Buy → Buy |
| 08/14/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 07/07/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 06/26/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 06/23/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 05/31/2023 | 1263.64% | Roth MKM | → $15 | Initiates Coverage On | → Buy |
| 04/28/2023 | 1445.45% | HC Wainwright & Co. | $20 → $17 | Maintains | Buy |
| 03/27/2023 | 1718.18% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 03/20/2023 | 1718.18% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 03/01/2023 | 309.09% | HC Wainwright & Co. | → $4.5 | Reiterates | → Buy |
| 02/27/2023 | 172.73% | Piper Sandler | $4 → $3 | Maintains | Overweight |
| 02/27/2023 | 309.09% | HC Wainwright & Co. | $7 → $4.5 | Maintains | Buy |
| 09/16/2022 | 263.64% | Piper Sandler | $3 → $4 | Maintains | Overweight |
| 08/15/2022 | 536.36% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 05/23/2022 | 172.73% | Piper Sandler | $8 → $3 | Maintains | Overweight |
| 07/09/2021 | 627.27% | Jefferies | → $8 | Initiates Coverage On | → Buy |
| 03/17/2021 | 627.27% | HC Wainwright & Co. | $5 → $8 | Maintains | Buy |
| 12/10/2019 | 354.55% | HC Wainwright & Co. | $2 → $5 | Reiterates | → Buy |
| 11/14/2019 | 81.82% | HC Wainwright & Co. | $9 → $2 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 1445.45% | HC Wainwright & Co. | → 17 美元 | 重申 | 購買 → 購買 |
| 08/14/2023 | 1263.64% | Roth MKM | → 15 美元 | 重申 | 購買 → 購買 |
| 08/14/2023 | 1445.45% | HC Wainwright & Co. | → 17 美元 | 重申 | 購買 → 購買 |
| 07/07/2023 | 1445.45% | HC Wainwright & Co. | → 17 美元 | 重申 | 購買 → 購買 |
| 06/26/2023 | 1445.45% | HC Wainwright & Co. | → 17 美元 | 重申 | 購買 → 購買 |
| 06/23/2023 | 1445.45% | HC Wainwright & Co. | → 17 美元 | 重申 | 購買 → 購買 |
| 05/31/2023 | 1263.64% | Roth MKM | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/28/2023 | 1445.45% | HC Wainwright & Co. | 20 美元 → 17 美元 | 維護 | 買 |
| 03/27/2023 | 1718.18% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 03/20/2023 | 1718.18% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 03/01/2023 | 309.09% | HC Wainwright & Co. | → 4.5 美元 | 重申 | → 購買 |
| 02/27/2023 | 172.73% | 派珀·桑德勒 | 4 美元 → 3 美元 | 維護 | 超重 |
| 02/27/2023 | 309.09% | HC Wainwright & Co. | 7 美元 → 4.5 美元 | 維護 | 買 |
| 2022 年 9 月 16 日 | 263.64% | 派珀·桑德勒 | 3 美元 → 4 美元 | 維護 | 超重 |
| 08/15/2022 | 536.36% | HC Wainwright & Co. | 8 美元 → 7 美元 | 維護 | 買 |
| 05/23/2022 | 172.73% | 派珀·桑德勒 | 8 美元 → 3 美元 | 維護 | 超重 |
| 07/09/2021 | 627.27% | 傑富瑞集團 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/17/2021 | 627.27% | HC Wainwright & Co. | 5 美元 → 8 美元 | 維護 | 買 |
| 2019 年 10 月 12 日 | 354.55% | HC Wainwright & Co. | 2 美元 → 5 美元 | 重申 | → 購買 |
| 11/14/2019 | 81.82% | HC Wainwright & Co. | 9 美元 → 2 美元 | 維護 | 買 |
What is the target price for ASLAN Pharma (ASLN)?
ASLAN Pharma (ASLN) 的目標價格是多少？
The latest price target for ASLAN Pharma (NASDAQ: ASLN) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $17.00 expecting ASLN to rise to within 12 months (a possible 1445.45% upside). 13 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月6日公佈了亞斯蘭製藥（納斯達克股票代碼：ASLN）的最新目標股價。該分析公司將目標股價定爲17.00美元，預計ASLN將在12個月內升至12個月內（可能上漲1445.45％）。去年有13家分析公司公佈了評級。
What is the most recent analyst rating for ASLAN Pharma (ASLN)?
分析師對ASLAN Pharma（ASLN）的最新評級是多少？
The latest analyst rating for ASLAN Pharma (NASDAQ: ASLN) was provided by HC Wainwright & Co., and ASLAN Pharma reiterated their buy rating.
ASLAN Pharma（納斯達克股票代碼：ASLN）的最新分析師評級由HC Wainwright & Co. 提供，ASLAN Pharma 重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for ASLAN Pharma (ASLN)?
ASLAN Pharma（ASLN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ASLAN Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ASLAN Pharma was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與ASLAN Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。ASLAN Pharma的最新評級是在2023年11月6日公佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating ASLAN Pharma (ASLN) correct?
分析師對ASLAN Pharma (ASLN) 的評級是否正確？
While ratings are subjective and will change, the latest ASLAN Pharma (ASLN) rating was a reiterated with a price target of $0.00 to $17.00. The current price ASLAN Pharma (ASLN) is trading at is $1.10, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的ASLAN Pharma（ASLN）評級，目標股價爲0.00美元至17.00美元。ASLAN Pharma（ASLN）目前的交易價格爲1.10美元，在分析師的預測區間內。